billHR3831Event Wednesday, May 20, 2026Analyzed

Florida Safe Seas Act of 2025

Neutral

Summary

HR 3831, the Florida Safe Seas Act of 2025, amends the Magnuson-Stevens Act to prohibit feeding sharks in federal waters off Florida. The bill has been reported by committee and placed on the Union Calendar, but authorizes no funding and imposes no direct economic burden on any publicly traded company. Market impact is negligible.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR 3831 imposes a narrow regulatory prohibition with zero funding authorization.
  • 2.No publicly traded company is directly affected by a ban on shark feeding in Florida's EEZ.
  • 3.The bill's progress through committee indicates likely passage, but market impact is nil.

Market Implications

This bill has no market implications. It does not authorize spending, create contracts, or impose compliance costs on any publicly traded entity. Investors should not allocate attention or capital based on this legislation.

Full Analysis

1) On May 20, 2026, the House Committee on Natural Resources reported HR 3831 (H. Rept. 119-658), placing it on the Union Calendar. The bill, introduced June 6, 2025 by Rep. Webster (R-FL-11), amends Section 317 of the Magnuson-Stevens Fishery Conservation and Management Act to add Florida to the existing prohibition on shark feeding in the exclusive economic zone off Hawaii. The bill has 5 cosponsors and has moved through subcommittee hearings and markup. 2) The bill authorizes zero funding. It is a regulatory prohibition, not a spending authorization or appropriation. No federal dollars are involved. 3) No publicly traded company has a business model dependent on feeding sharks in Florida's EEZ. The prohibition affects recreational charter operators and individual boaters, none of which are publicly traded entities. No tickers are affected. 4) No real market data is provided. The legislative history shows steady progress through committee, but the bill's narrow scope precludes any material market impact. 5) The bill must pass the full House and Senate, then be signed by the President. Given its non-controversial nature and committee support, passage is plausible but market-irrelevant.